Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback